

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY .....	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT .....	2
METHODOLOGY .....	2
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS .....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER .....	4
 CHAPTER TWO: SUMMARY.....	 5
SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL MARKET FORECAST FOR ONCOLOGY</i>	
<i>ADJUVANTS, THROUGH 2015 (\$ MILLIONS)</i> .....	6
<i>SUMMARY FIGURE GLOBAL ONCOLOGY ADJUVANT SALES BY</i>	
<i>MARKET GEOGRAPHY, 2009 AND 2015 (%)</i> .....	6
<i>SUMMARY FIGURE (CONTINUED)</i> .....	7
 CHAPTER THREE: OVERVIEW .....	 8
HISTORY AND CURRENT STATE OF ONCOLOGY AND	
CONCEPTS OF ADJUVANTS IN ONCOLOGY.....	8
HISTORY AND CURRENT STATE OF ...(CONTINUED) .....	9
TYPES OF CANCER .....	10
DEFINITION OF THE INDUSTRY .....	10
IMPORTANCE OF THE INDUSTRY .....	11
PRODUCT LIFE CYCLES .....	12
<i>TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING</i>	
<i>DISCOVERY OF NEW DRUG</i> .....	12
DEVELOPMENT OF ONCOLOGY ADJUVANTS .....	13
<i>TABLE 2 HISTORICAL PIPELINE OF FDA-APPROVED ONCOLOGY</i>	
<i>ADJUVANTS</i> .....	13
HUMAN CLINICAL DEVELOPMENT .....	14
NEW DRUG ACTIVITY .....	14
FUTURE DEVELOPMENTS .....	15
2008 TO 2009 DRUG ACTIVITY .....	15
2008 TO 2009 DRUG ACTIVITY (CONTINUED) .....	16
WITH AN EYE TOWARD THE FUTURE.....	17
 CHAPTER FOUR: TYPE OF APPLICATIONS IN THE HUMAN	
ONCOLOGY ADJUVANT MARKETPLACE: CHEMOTHERAPY,	
IMMUNOTHERAPY, AND RADIOTHERAPY.....	18

<i>TABLE 3 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS SALES BY PRODUCT TYPE, THROUGH 2015 (\$ MILLIONS)</i> .....	19
<i>FIGURE 1 ONCOLOGY ADJUVANTS SALES: BY ADJUNCTIVE PRODUCT TYPE, 2008-2015 (\$ MILLIONS)</i> .....	19
CHAPTER FIVE: HUMAN CANCERS .....	20
<i>TABLE 4 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS BY CANCER INDICATION, THROUGH 2015 (\$ MILLIONS)</i> .....	20
<i>FIGURE 2 ONCOLOGY ADJUVANTS FORECAST SALES: BY TYPE OF CANCER 2008-2015 (\$ MILLIONS)</i> .....	21
RISK FACTORS FOR DEVELOPING CANCERS .....	21
<i>TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN CANCERS</i> .....	22
<i>TABLE 5 (CONTINUED)</i> .....	23
<i>TABLE 6 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN MEN</i> .....	24
<i>TABLE 7 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN WOMEN</i> .....	24
<i>TABLE 8 HUMAN CANCER TRENDS, ESTIMATED, 2008-2015 (NUMBER OF CASES)</i> .....	25
BREAST.....	25
<i>TABLE 9 GLOBAL SALES FORECAST OF BREAST CANCER ONCOLOGY ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	26
RECTUM AND COLON.....	26
<i>TABLE 10 GLOBAL SALES FORECAST OF COLORECTAL CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	27
NON-HODGKIN LYMPHOMAS.....	27
<i>TABLE 11 GLOBAL SALES FORECAST OF LYMPHOMAS ADJUVANTS BY GEORGRAPHYGEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	28
LUNG.....	28
<i>TABLE 12 GLOBAL SALES FORECAST OF LUNG CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	29
LEUKEMIA .....	29
<i>TABLE 13 GLOBAL SALES FORECAST OF LEUKEMIA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	30
PROSTATE CANCER.....	30
<i>TABLE 14 GLOBAL SALES FORECAST OF PROSTATE CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	30
GLIOBLASTOMA .....	31
<i>TABLE 15 GLOBAL SALES FORECAST OF GLIOBLASTOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	31
MULTIPLE MYELOMA .....	31

<i>TABLE 16 GLOBAL SALES FORECAST OF MULTIPLE MYELOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i>	32
GASTRIC	32
<i>TABLE 17 GLOBAL SALES FORECAST OF GASTRIC CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i>	33
<i>TABLE 18 GLOBAL SALES FORECAST OF ALL OTHER ONCOLOGY ADJUVANTS SALES BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i>	33
KIDNEY	34
OVARY	34
PANCREAS	34
URINARY BLADDER	35
UTERINE CERVIX	35
SKIN CANCER	36
TUMOR TYPES AND STAGES	36
<i>TABLE 19 ADJUVANTS UTILIZED BY STAGE OF CANCER BY INDICATION</i>	37
<i>TABLE 20 SIDE EFFECTS OF ADJUVANT THERAPEUTICS</i>	38
<i>TABLE 20 (CONTINUED)</i>	39
CHAPTER SIX: HUMAN ONCOLOGY ADJUVANTS	40
<i>TABLE 21 GLOBAL SALES FORECAST OF ONCOLOGY ADJUVANTS CONSUMPTION BY BRANDED VS. GENERIC ALL PRODUCT TYPES OF ADJUVANTS, THROUGH 2015 (\$ MILLIONS)</i>	40
<i>FIGURE 3 GLOBAL SALES FORECAST OF ONCOLOGY ADJUVANTS CONSUMPTION BY BRANDED VS. GENERIC ALL PRODUCT TYPES OF ADJUVANTS, 2008-2015 (\$ MILLIONS)</i>	41
CHEMOTHERAPIES	41
<i>TABLE 22 GLOBAL SALES FORECAST OF CHEMOTHERAPIES BY CANCER INDICATION, THROUGH 2015 (\$ MILLIONS)</i>	42
<i>FIGURE 4 GLOBAL SALES FORECAST OF CHEMOTHERAPIES BY CANCER INDICATION, 2008-2015 (\$ MILLIONS)</i>	42
<i>TABLE 23 GLOBAL SALES FORECAST OF BRANDED VS. GENERIC CHEMOTHERAPIES, THROUGH 2015 (\$ MILLIONS)</i>	43
IMMUNOTHERAPIES	43
<i>TABLE 24 GLOBAL SALES FORECAST OF IMMUNOTHERAPIES BY CANCER INDICATION, THROUGH 2015 (\$ MILLIONS)</i>	44
<i>FIGURE 5 GLOBAL SALES FORECAST OF IMMUNOTHERAPIES BY CANCER INDICATION, THROUGH 2008-2015 (\$ MILLIONS)</i>	44
<i>TABLE 25 GLOBAL SALES FORECAST OF BRANDED VS. GENERIC IMMUNOTHERAPIES, THROUGH 2015 (\$ MILLIONS)</i>	45
RADIOTHERAPEUTICS	45
<i>TABLE 26 GLOBAL SALES FORECAST OF BRANDED VS. GENERIC RADIOTHERAPIES, THROUGH 2015 (\$ MILLIONS)</i>	45

<i>FIGURE 6 GLOBAL SALES FORECAST OF RADIOTHERAPEUTICS BY CANCER BRANDED AND GENERIC, 2008-2015 (\$ MILLIONS)</i> .....	46
OTHER .....	46
<i>TABLE 27 GLOBAL SALES FORECAST FOR GENERIC ONCOLOGY ADJUVANTS CHEMOTHERAPIES AND RADIOTHERAPIES, THROUGH 2015 (\$ MILLIONS)</i> .....	47
<i>FIGURE 7 GLOBAL SALES FORECAST OF GENERIC ONCOLOGY ADJUVANTS CHEMOTHERAPIES AND RADIOTHERAPIES, 2008- 2015 (\$ MILLIONS)</i> .....	47
<i>TABLE 28 GLOBAL SALES FORECAST OF GENERIC ONCOLOGY ADJUVANTS BROKEN DOWN BY CANCER INDICATION, THROUGH 2015 (\$ MILLIONS)</i> .....	48
<i>FIGURE 8 GLOBAL SALES FORECAST OF GENERIC ONCOLOGY ADJUVANTS BY CANCER INDICATION, 2008-2015 (\$ MILLIONS)</i> .....	48
<i>TABLE 29 GLOBAL SALES FORECAST OF CHEMOTHERAPEUTICS BROKEN DOWN BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	49
<i>TABLE 30 GLOBAL SALES FORECAST OF IMMUNOTHERAPIES BROKEN DOWN BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	49
<i>TABLE 31 GLOBAL SALES FORECAST OF RADIOTHERAPIES BROKEN DOWN BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	49
<i>TABLE 32 GLOBAL SALES FORECAST OF ONCOLOGY ADJUVANTS BY ROUTES OF ADMINISTRATION, THROUGH 2015 (\$ MILLIONS)</i> .....	50
<i>FIGURE 9 GLOBAL SALES FORECAST OF ONCOLOGY ADJUVANTS BY ROUTES OF ADMINISTRATION, 2008-2015 (\$ MILLIONS)</i> .....	50
<i>TABLE 33 LIST OF CHEMOTHERAPIES AND THEIR ADJUVANTS AND FOR WHICH CANCER THEY ARE INDICATED</i> .....	51
<i>TABLE 33 (CONTINUED)</i> .....	52
TREATMENT COST DATA .....	52
<i>TABLE 34 PRICE OF MAJOR ONCOLOGY ADJUVANTS BY COMBINATION IN PRICE PER MONTH MOST CURRENT DATA, 2005-2006 (\$)</i> .....	53
 CHAPTER SEVEN: TRADITIONAL MEDICINES .....	 54
A BRIEF HISTORY OF NATURAL MEDICINES .....	54
MORE CURRENT FDA APPROVALS OF NATURAL MEDICINES .....	55
NATURAL PRODUCTS IN CLINICAL TRIALS .....	56
<i>TABLE 35 NATURAL AGENTS WITH REFERENCES TO CLINICAL TRIALS</i> .....	56
<i>TABLE 35 (CONTINUED)</i> .....	57
SELECTED SUMMARIES OF HERBAL/NATURAL ADJUVANTS THAT ARE NOT LISTED IN CLINICAL DATABASES .....	58
<i>TABLE 36 OTHER TRADITIONAL THERAPIES NOT LISTED IN CLINICAL TRIALS DATABASES</i> .....	58
<i>TABLE 36 (CONTINUED)</i> .....	59
<i>TABLE 37 COMMON HERBAL ONCOLOGY ADJUVANTS</i> .....	60

CHAPTER EIGHT: GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS .....	61
FOOD AND DRUG ADMINISTRATION .....	61
FOOD AND DRUG ADMINISTRATION (CONTINUED) .....	62
<i>TABLE 38 ONCOLOGY ADJUVANT WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA: 1997-2009</i> .....	63
<i>TABLE 38 (CONTINUED)</i> .....	64
ENVIRONMENTAL PROTECTION AGENCY (EPA).....	64
PROFESSIONAL ASSOCIATIONS.....	65
AMERICAN ASSOCIATION FOR CANCER RESEARCH.....	65
AMERICAN SOCIETY OF CLINICAL ONCOLOGY: ASCO .....	66
 CHAPTER NINE: MAJOR ONCOLOGY ADJUVANTS MANUFACTURERS .....	67
MAJOR BRANDED MANUFACTURERS.....	67
<i>TABLE 39 MAJOR ONCOLOGY ADJUVANT HUMAN PHARMACEUTICAL MANUFACTURERS</i> .....	68
<i>FIGURE 10 PERCENTAGE OF ONCOLOGY ADJUVANT PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%)</i> .....	68
<i>FIGURE 10 (CONTINUED)</i> .....	69
<i>TABLE 40 MAJOR PHARMACEUTICAL ONCOLOGY ADJUVANT MANUFACTURERS, 2009 (\$ BILLIONS)</i> .....	69
MAJOR PHARMACEUTICAL MANUFACTURER PROFILES .....	69
ABRAXIS BIOSCIENCE CORPORATE HEADQUARTERS.....	70
AMGEN INC.....	70
ASTRAZENECA PLC.....	70
BIOGEN.....	71
BMS .....	71
CELGENE CORPORATION.....	72
ENZON PHARMACEUTICALS, INC. ....	72
GENENTECH, INC. ....	73
GSK.....	73
MERCK.....	74
ELI LILLY CO.....	74
NOVARTIS .....	74
OSI PHARMACEUTICALS, INC. ....	75
SANOFI-AVENTIS .....	75
PFIZER, INC. ....	76
F. HOFFMANN-LA ROCHE LTD .....	76
VALEANT.....	76
GENERIC MARKET.....	77
<i>TABLE 41 MAJOR GENERIC ONCOLOGY ADJUVANTS MANUFACTURERS AND PRODUCTS</i> .....	77
GENERIC PHARMACEUTICAL MANUFACTURER PROFILES.....	78
ACCORD HEALTHCARE INC.....	78
ACTAVIS TOTOWA.....	78

BEDFORD LABORATORIES.....	78
FRESENIUS KABI ONCOLOGY .....	79
HOSPIRA, INC.....	79
STASON PHARMACEUTICALS, INC .....	80
SUN PHARMA INDUS LTD .....	80
TEVA PHARMACEUTICAL INDUSTRIES LTD.....	80
WATSON LABS .....	81
TRADITIONAL/ALTERNATIVE MEDICINE MANUFACTURER PROFILES .....	81
<i>TABLE 42 COMMONLY AVAILABLE ALTERNATIVE ONCOLOGY ADJUVANTS .....</i>	
AMERICAN FORMULARY, INC. ....	82
AMERICAN BIOLOGICS .....	82
BLUEBONNET NUTRITION CORP. ....	83
CVC4HEALTH.COM .....	83
COUNTRY LIFE, LLC.....	83
ENZYMATIC THERAPY, INC. ....	84
FOODSCIENCE OF VERMONT.....	84
HERBASWAY.....	84
LIFE EXTENSION FOUNDATION.....	85
NATURE'S ANSWER .....	85
PREMIER RESEARCH LABS.....	85
CHAPTER TEN: ONCOLOGY ADJUVANTS INDUSTRY.....	86
ONCOLOGY ADJUVANT MARKET TRENDS: HUMAN HEALTHCARE.....	86
ACCELERATING ONCOLOGY ADJUVANT DRUG DEVELOPMENT .....	86
BREAST CANCER.....	87
COLORECTAL CANCER.....	88
SARCOMA.....	88
GLIOBLASTOMA .....	88
HODGKIN'S LYMPHOMA.....	89
LUNG .....	89
OVARIAN.....	89
PROSTATE .....	89
<i>TABLE 43 PHARMACEUTICAL ONCOLOGY ADJUVANTS PRODUCTS IN THE PIPELINE, 2009.....</i>	
<i>TABLE 44 NEW PRESCRIPTION ONCOLOGY ADJUVANTS THROUGH 2009.....</i>	
NEED TO INCREASE USE AND ACCEPTANCE OF NEWER DRUGS .....	90
Need to Increase Use and Acceptance ... (Continued).....	91
CHAPTER ELEVEN: PATENT ANALYSIS .....	92
PURPOSE OF A PATENT ANALYSIS.....	92

DUE CARE IN REVIEWING THE PATENT ANALYSIS .....	92
NEW ONCOLOGY ADJUVANTS PATENTS ISSUED .....	93
TABLE 45 ONCOLOGY ADJUVANT PATENT TRENDS, 1990-2010 .....	94
ONCOLOGY ADJUVANT PATENT TRENDS, 1990–2009.....	94
TABLE 46 PATENTS BY ONCOLOGY ADJUVANT – THERAPY TYPE, 1990- 2009 .....	95
TABLE 47 NEW ONCOLOGY ADJUVANTS PATENTS ISSUED, 2008- 2009 .....	95
TABLE 47 (CONTINUED).....	96
TABLE 47 (CONTINUED).....	97
TABLE 47 (CONTINUED).....	98
TABLE 48 ASSIGNEES OF TWO OR MORE PATENTS FOR ONCOLOGY ADJUVANT PRODUCTS, 2008 THROUGH 2009.....	98
TABLE 49 PATENT TRENDS BY COUNTRY, 2008-2009.....	99
FIGURE 11 NEW ONCOLOGY ADJUVANT PATENT APPROVALS BY COUNTRY, 2008-2009 (%) .....	99
TRENDS IN PATENT APPLICATIONS .....	100
TABLE 50 TOTAL ONCOLOGY ADJUVANT PATENT APPLICATION TRENDS, 2001-2009.....	100
FIGURE 12 ONCOLOGY ADJUVANT PATENT APPLICATIONS BY YEAR, 2001-2009 (%).....	101
TABLE 51 PATENT APPLICATIONS BY ONCOLOGY ADJUVANT THERAPY TYPE, 2008-2009.....	101
FIGURE 13 PERCENTAGE OF PATENT APPLICATIONS BY ONCOLOGY ADJUVANT THERAPY TYPE, 2008-2009 (%).....	102
TABLE 52 NEW PATENT APPLICATIONS, 2008 THROUGH 2009.....	102
TABLE 52 (CONTINUED).....	103
TABLE 52 (CONTINUED).....	104
TABLE 52 (CONTINUED).....	105
TABLE 52 (CONTINUED).....	106
TABLE 52 (CONTINUED).....	107
TABLE 52 (CONTINUED).....	108
TABLE 52 (CONTINUED).....	109
TABLE 52 (CONTINUED).....	110
TABLE 52 (CONTINUED).....	111
TABLE 52 (CONTINUED).....	112
TABLE 52 (CONTINUED).....	113
TABLE 52 (CONTINUED).....	114
TABLE 52 (CONTINUED).....	115
TABLE 52 (CONTINUED).....	116
TABLE 52 (CONTINUED).....	117
TABLE 52 (CONTINUED).....	118
TABLE 52 (CONTINUED).....	119
TABLE 53 PATENT APPLICATION TRENDS BY COUNTRY, 2008-2009....	119

<i>TABLE 53 (CONTINUED)</i> .....	120
<i>FIGURE 14 ONCOLOGY ADJUVANT PATENT APPLICATIONS BY</i>	
<i>COUNTRY, 2008-2009 (%)</i> .....	120
<i>PATENT EXPIRATIONS</i> .....	120
<i>TABLE 54 PATENT EXPIRATIONS, 2006-2011</i> .....	121
APPENDIX .....	122
<i>TABLE 55 PHARMACEUTICAL COMPANIES</i> .....	122
<i>TABLE 55 (CONTINUED)</i> .....	123
<i>TABLE 55 (CONTINUED)</i> .....	124
<i>TABLE 55 (CONTINUED)</i> .....	125
<i>TABLE 55 (CONTINUED)</i> .....	126